In The News
Child removal class actions launched against NSW, WA
Slater & Gordon denies firing HR head for reporting underpayments
Class action dropped against Westpac unit, applicant to get $1.5M costs
Social media companies to face $50M fine for violating under 16 ban
Banned financial advisor faces charges over undisclosed commissions
CBA slams class actions’ ‘misguided’ theory on appeal
Judgment in CBA class actions could affect insider trading cases, Full Court told
Second law firm investigating class action against Coles, Woolworths
NSW police can’t subpoena group members’ names in strip search class action
Judge calls out Corrs Chambers’ ‘combative’ conduct in building defects suit
Please login to bookmarkClose

South Korean biosimilars company Samsung Bioepis has sued Johnson & Johnson’s Janssen Biotech to invalidate two patents for Crohn’s disease drug Stelara, after reaching a licencing agreement over the medicine in the US.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au